Biotech New Highs: Five Prime Therapeutics Inc (NASDAQ:FPRX), Albany Molecular Research (NASDAQ:AMRI), Vanda Pharmaceuticals (NASDAQ:VNDA), Chimerix Inc (NASDAQ:CMRX)

Five Prime therapeutics Inc. (NASDAQ:FPRX) has announced it has entered into a collaboration agreement with Bristol Myers Squibb Co (NYSE:BMY) for the discovery and development of immune-oncology therapies. Five Prime Therapeutics Inc (NASDAQ:FPRX) stock performance was 22.61% in last session and finished the day at $22.99. Traded volume was 1,287,393 million shares in the last session and the average volume of the stock remained 120.37 … Continue reading Biotech New Highs: Five Prime Therapeutics Inc (NASDAQ:FPRX), Albany Molecular Research (NASDAQ:AMRI), Vanda Pharmaceuticals (NASDAQ:VNDA), Chimerix Inc (NASDAQ:CMRX)

Stocks Moving After-Hours: Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Kinder Morgan Management (NYSE:KMR), FutureFuel (NYSE:FF)

Citigroup upgraded it rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company’s Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron’s pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron (REGN) closed … Continue reading Stocks Moving After-Hours: Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Kinder Morgan Management (NYSE:KMR), FutureFuel (NYSE:FF)

TrovaGene (NASDAQ:TROV) reported that for Q4, it narrowed its loss year over year, beating Street estimates, while revenue fell versus the prior year period and fell short of analysts’ expectations. The development-stage molecular diagnostic company reported a Q4 net loss of $1 million, or $0.05 per share, compared with the prior-year period’s net loss of $6.3 million, or $0.43 per share. Revenue was $47,000 down … Continue reading Healthcare Stocks to Watch: TrovaGene (NASDAQ:TROV), AstraZeneca plc (ADR) (NYSE:AZN), Life Partners Holdings Inc. (NASDAQ:LPHI), Alliance HealthCare Services Inc. (NASDAQ:AIQ)

Discovery Laboratories, Inc. (NASDAQ:DSCO) has been upgraded by TheStreet Ratings from sell to hold. Discovery Laboratories, Inc. (NASDAQ:DSCO) stock performance was -6.01% in last session and finished the day at $2.19. Traded volume was 1,245,476 million shares in the last session and the average volume of the stock remained 589.46 million shares. The beta of the stock remained 1.35. Discovery Laboratories, Inc. (NASDAQ:DSCO) insider ownership … Continue reading Biotech Losers: Discovery Laboratories (NASDAQ:DSCO), CEL-SCI Corporation (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), La Jolla Pharmaceutical (NASDAQ:LJPC)

Sirius XM (NASDAQ:SIRI) has received another vote of confidence this week, this time from Evercore which reinstated an “overweight” rating on the satellite radio company in the aftermath of the failed buyout attempt from Liberty Media Sirius XM Holdings Inc. (NASDAQ:SIRI) stock performance was -0.58% in last session and finished the day at $3.42. Traded volume was 50.08 million shares in the last session and … Continue reading Services Sector Active Stocks: Sirius XM Holdings (NASDAQ:SIRI), Hertz Global Holdings (NYSE:HTZ), Rite Aid (NYSE:RAD), Comcast Corporation (NASDAQ:CMCSA)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and … Continue reading Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)